Stockwinners Market Radar for November 07, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. FiscalNote Holdings, a Washington, D.C.-based provider of services used to track government policy and owner of the CQ Roll Call publication, is in talks to go public through a merger with special-purpose acquisition company Duddell Street Acquisition (DSAC) at a valuation of $1.3B, The Wall Street Journal's Ben Dummett and Julie Steinberg reported, citing people familiar with the matter. Duddell and FiscalNote's backers Mark Cuban, Jerry Yang and S&P Global (SPGI) will remain shareholders as part of the merger plan, sources told the Journal. The deal could be announced as soon as Monday, they added. 2. Twitter users overwhelmingly voted in favor of Tesla (TSLA) CEO Elon Musk selling 10% of his shares in the electric car maker. Musk said he would follow the poll's results as he posted it. With 3.52M votes counted, Twitter users voted 58% in support of Musk selling 10% of his holdings. "Much is made lately of unrealized gains being a means of tax avoidance, so I propose selling 10% of my Tesla stock. Do you support this?," Musk asked Twitter users. "I will abide by the results of this poll, whichever way it goes," he added. 3. Rivian Automotive (RIVN) is set to go public this coming week at a market value that could exceed that of Honda Motor (HMC) despite having sold just a handful of vehicles, but that's not as crazy as it sounds, Al Root wrote in this week's edition of Baron's. To many, a market cap around $64 billion makes no sense. However, the company has powerful backers - Ford (F) and Amazon (AMZN) - and a dive into the math suggests the valuation "isn't quite as nuts as it looks," the author noted. 4. Disney's (DIS) and Marvel's "Eternals" won this weekend's domestic box office with a $71M debut from 4,090 theaters, faring better overseas for a worldwide kickoff of $161.7M, the second biggest opening of the COVID era. The movie sports a B CinemaScore and a 49% Rotten Tomatoes Score, the lowest of any title in the Marvel Cinematic Universe. 5. Alleghany (Y) and Blade Air Mobility (BLDE) saw positive mentions in this week's edition of Barron's.

15:39 EST FirstEnergy to sell stake in transmission business to Brookfield - FirstEnergy (FE) announced two financings with Blackstone Infrastructure Partners and Brookfield Super-Core Infrastructure Partners that will raise a combined $3.4 billion in equity proceeds "to strengthen FirstEnergy's financial position, capitalize on incremental investment opportunities and address all equity plans," the company said. FirstEnergy also introduced a long-term EPS growth rate of 6%-8%. FirstEnergy announced an agreement to issue $1 billion of common equity to Blackstone Infrastructure Partners, Blackstone's (BX) dedicated-infrastructure group, at $39.08 per share, which is equal to FirstEnergy's common equity five-day volume-weighted average price as of the market close on Friday, November 5, 2021. FirstEnergy will appoint a Blackstone Infrastructure Partners-selected representative to its board of directors no later than the next annual meeting. FirstEnergy has also entered into a definitive agreement with Brookfield (BAM) to sell a 19.9% stake in FET, the holding company for FirstEnergy's three regulated transmission subsidiaries, for $2.4 billion, representing an exceptionally attractive electric utility valuation of 40x LTM P/E. The company also announced a $2.2 billion increase to its capital investment plan through 2025, which now totals $17 billion from 2021 to 2025, including $10 billion in sustainable energy investments.

15:22 EST Medtronic announces early data for Intrepid TMVR system - Medtronic presented early data for its self-expanding Intrepid transcatheter mitral valve replacement system in patients with severe, symptomatic mitral valve regurgitation utilizing the transfemoral access route. Presented as Late-Breaking Clinical Science at the 33rd Transcatheter Cardiovascular Therapeutics conference, the annual scientific symposium of the Cardiovascular Research Foundation, data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days. The data were published simultaneously in the Journal of the American College of Cardiology: Cardiovascular Intervention. The Intrepid valve has been used to treat more than 350 patients as part of global clinical trials. Currently, the Medtronic APOLLO Trial is evaluating the Intrepid TMVR system in patients with severe MR with one cohort evaluating patients with primary or secondary MR who are unsuitable for conventional mitral valve surgery or transcatheter edge-to-edge repair. A second cohort is evaluating patients with severe symptomatic MR who are deemed ineligible for conventional mitral valve surgery with mitral annular calcification. To date, patients enrolled in the study have received the Intrepid TMVR system using the transapical access route where the valve is compressed inside a hollow catheter and inserted between the ribs into the heart. With IDE approval, APOLLO study investigators will now have the additional option to insert the valve via an incision in the groin into the femoral vein, which has historically been the preferred approach for most transcatheter procedures. The Intrepid TMVR system, which received Breakthrough Device Designation from FDA, integrates self-expanding, dual-stent technology with a replacement tissue heart valve to facilitate a catheter-based implantation. Using a delivery catheter to insert the valve into the heart, the new replacement valve is expanded directly into the malfunctioning mitral valve. The outer stent frame is designed to attach and conform to the native valve without the need for additional sutures, tethers, or anchors to secure the prosthesis. The inner stent houses the valve, which is made from bovine tissue and is intended to maintain blood flow.